Systematic review of combination therapies for mycosis fungoides

Cancer Treatment Reviews

Volumn 40, Issue 8, 2014, Pages 927-933

  Humme, Daniel ^a   Nast, Alexander ^a   Erdmann, Ricardo ^a   Vandersee, Staffan ^a   Beyer, Marc ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bexarotene; Combination therapy; Interferon alpha; Mycosis fungoides; Puva; Systematic review

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; GEMCITABINE; METHOTREXATE; PSORALEN; RETINOID; VORINOSTAT;

CANCER COMBINATION CHEMOTHERAPY; HUMAN; MYCOSIS FUNGOIDES; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BEXAROTENE; COMBINATION THERAPY; INTERFERON-ALPHA; MYCOSIS FUNGOIDES; PUVA; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FICUSIN; HUMANS; HYDROXAMIC ACIDS; INTERFERON-ALPHA; METHOTREXATE; MYCOSIS FUNGOIDES; PHOTOTHERAPY; RETINOIDS; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 84904798777     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.06.005     Document Type: Review

References (73)

1. Kim Y.H., Liu H.L., Mraz-Gernhard S., Varghese A., Hoppe R.T. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003, 139(7):857-866.
2. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105(10):3768-3785.
3. Stadler R., Assaf C., Klemke C.D., et al. Brief S2k guidelines - cutaneous lymphomas. J Dtsch Dermatol Ges 2013, 11(Suppl. 3):19-28. 20-30.
4. Dummer R., Dreyling M., ESMO Guidelines Working Group Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl. 2):ii72-6.
5. Bunn P.A., Ihde D.C., Foon K.A. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986, 57(8 Suppl.):1689-1695.
6. Nicolas J.F., Balblanc J.C., Frappaz A., Chouvet B., Delcombel M., Thivolet J. Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a. Dermatologica 1989, 179(1):34-37.
7. Whittaker S.J., Marsden J.R., Spittle M., Russell Jones R. Association of Dermatologists, U.K. Cutaneous Lymphoma Group, Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003, 149(6):1095-1107.
8. Sugaya M., Hamada T., Kawai K., Yonekura K., Ohtsuka M., Shimauchi T., et al. Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group. J Dermatol 2013, 40(1):2-14.
9. Trautinger F., Knobler R., Willemze R., Peris K., Stadler R., Laroche L., et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006, 42(8):1014-1030.
10. Zouboulis C.C. Retinoids-which dermatological indications will benefit in the near future?. Skin Pharmacol Appl Skin Physiol 2001, 14(5):303-315.
11. Hurst R.E. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 2000, 1(4):514-523.
12. Qu L., Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother Pharmacol 2010, 65(2):201-205.
13. Terhorst D., Mestel D.S., Humme D., Sterry W., Beyer M. Evaluation of different methods in the follow-up of patients with indolent types of primary cutaneous lymphomas. Br J Dermatol 2012, 166(6):1295-1300.
14. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology 2007, 21(2 Suppl. 1):33-40.
15. Le Tourneau C., Lee J.J., Siu L.L. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009, 101(10):708-720.
16. OCEBM Levels of Evidence Working Group*. "The Oxford Levels of Evidence 2". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653.
17. Stadler R., Otte H.G., Luger T., Henz B.M., Kühl P., Zwingers T., et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998, 92(10):3578-3581.
18. Roenigk H.H., Kuzel T.M., Skoutelis A.P., Springer E., Yu G., Caro W., et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990, 95(6 Suppl.):198S-205S.
19. Nikolaou V., Siakantaris M.P., Vassilakopoulos T.P., Papadavid E., Stratigos A., Economidi A., et al. PUVA plus interferon aα-2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series. J Eur Acad Dermatol Venereol 2011, 25(3):354-357.
20. Rupoli S., Goteri G., Pulini S., Filosa A., Tassetti A., Offidani M., et al. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. Eur J Haematol 2005, 75(2):136-145.
21. Chiarion-Sileni V., Bononi A., Fornasa C.V., Soraru M., Alaibac M., Ferrazzi E., et al. Phase II trial of interferon-alpha-2a plus psoralen with ultraviolet light A in patients with cutaneous T-cell lymphoma. Cancer 2002, 95(3):569-575.
22. Stadler R., Otte H.G. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy. Recent Results Cancer Res 1995, 139:391-401.
23. Hüsken A.C., Tsianakas A., Hensen P., Nashan D., Loquai C., Beissert S., et al. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012, 26(1):71-78.
24. Kujawska A., Abrou A., Fivenson D.P., Lim H.W. PUVA vs PUVA and interferon alpha for treatment of mycosis fungoides. J Invest Dermatol 2003, 121(1):1185.
25. Mostow E.N., Neckel S.L., Oberhelman L., Anderson T.F., Cooper K.D. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993, 129(6):747-752.
26. Wozniak M.B., Tracey L., Ortiz-Romero P.L., Montes S., Alvarez M., Fraga J., et al. Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. Br J Dermatol 2009, 160(1):92-102.
27. Stadler R., Kremer A., Luger T., Sterry W. Prospective, randomized, multicentre clinical trial on the use of interferon a2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II. J Clin Oncol 2006, 24(18S):7541.
28. Singh F., Lebwohl M.G. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004, 51(4):570-573.
29. Whittaker S., Ortiz P., Dummer R., Ranki A., Hasan B., Meulemans B., et al. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA)compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol 2012, 167(suppl. 3):678-687.
30. Papadavid E., Antoniou C., Nikolaou V., Siakantaris M., Vassilakopoulos T.P., Stratigos A., et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol 2008, 9(3):169-173.
31. Thomsen K., Hammar H., Molin L., Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989, 69(6):536-538.
32. Serri F., De Simone C., Venier A., Rusciani L., Marchetti F. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Curr Probl Dermatol 1990, 19:252-257.
33. Delfino C., Grandi V., Pileri A., Rupoli S., Quaglino P., Alterini R., et al. Combination treatment in CTCL: the current role of bexarotene. G Ital Dermatol Venereol 2012, 147(6):573-580.
34. Altomare G.F., Capella G.L., Pigatto P.D., Finzi A.F. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993, 32(2):138-141.
35. Dréno B., Claudy A., Meynadier J., Verret J.L., Souteyrand P., Ortonne J.P., et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991, 125(5):456-459.
36. Thestrup-Pedersen K., Hammer R., Kaltoft K., Sogaard H., Zachariae H. Treatment of mycosis fungoides with recombinant interferon-alpha 2a alone and in combination with etretinate. Br J Dermatol 1988, 118(6):811-818.
37. Knobler R.M., Trautinger F., Radaszkiewicz T., Kokoschka E.M., Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991, 24:247-252.
38. Avilés A., Nambo M.J., Neri N., Castañeda C., Cleto S., Gonzalez M., et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. Cancer Biother Radiopharm 2007, 22(6):836-840.
39. Wollina U., Looks A., Meyer J., Knopf B., Koch H.J., Liebold K., et al. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. J Am Acad Dermatol 2001, 44(2):253-260.
40. Dummer R., Beyer M., Hymes K., Epping M.T., Bernards R., Steinhoff M., et al. Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma 2012, 53(8):1501-1508.
41. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109-3115.
42. Duvic M., Martin A.G., Kim Y., Olsen E., Wood G.S., Crowley C.A., et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001, 137:581-593.
43. Kannangara A.P., Levitan D., Fleischer A.B. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma. J Dermatolog Treat 2009, 20(3):169-176.
44. Duvic M., Hymes K., Heald P., Breneman D., Martin A.G., Myskowski P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001, 19(9):2456-2471.
45. Illidge T., Chan C., Counsell N., Morris S., Scarisbrick J., Gilson D., et al. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 2013, 109(10):2566-2573.
46. Groth O., Molin L., Thomsen K. Tumour stage of mycosis fungoides treated with bleomycin and methotrexate: report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol 1979, 59(1):59-63.
47. Schappell D.L., Alper J.C., McDonald C.J. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermatol 1995, 131(3):307-313.
48. Lundin J., Osterborg A. Therapy for mycosis fungoides. Curr Treat Options Oncol 2004, 5(3):203-214.
49. Mestel D.S., Beyer M., Steinhoff M., Sterry W., Assaf C. The treatment of mycosis fungoides. G Ital Dermatol Venereol 2008, 143(6):395-408.
50. Lansigan F., Foss F.M. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010, 70(3):273-286.
51. Weberschock T., Strametz R., Lorenz M., Röllig C., Bunch C., Bauer A., et al. Interventions for mycosis fungoides. Cochrane Database Syst Rev 2012, 9:CD008946. [12].
52. van Doorn R., Van Haselen C.W., van Voorst Vader P.C., Geerts M.L., Heule F., de Rie M., et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000, 136(4):504-510.
53. Olsen E.A., Whittaker S., Kim Y.H., Duvic M., Prince H.M., Lessin S.R., et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011, 29:2598-2607.
54. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110(6):1713-1722.
55. Searles A.D., Lee A.D., Feldman S.R. Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination. J Am Acad Dermatol 2011, 64(4):791-793.
56. Kuzel T.M. Systemic chemotherapy for the treatment of mycosis fungoides and Sézary syndrome. Dermatol Ther 2003, 16(4):355-361.
57. Kaye F.J., Bunn P.A., Steinberg S.M., Stocker J.L., Ihde D.C., Fischmann A.B., et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989, 321(26):1784-1790.
58. Grozea P.N., Jones S.E., McKelvey E.M., Coltman C.A., Fisher R., Haskins C.L. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep 1979, 63(4):647-653.
59. Leavell U.W., DeSimone P. Combined chemotherapy (COP) in treatment of mycosis fungoides: report of four cases. South Med J 1976, 69(7):915-917.
60. Sentis H.J., Willemze R., Van Vloten W.A. Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. Acta Derm Venereol 1985, 65(2):179-183.
61. Fierro M.T., Quaglino P., Savoia P., Verrone A., Bernengo M.G. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998, 31(5-6):583-588.
62. Case D.C. Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone. Am J Clin Oncol 1984, 7(5):453-455.
63. Dummer R., Quaglino P., Becker J.C., et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012, 30(33):4091-4097.
64. Di Lorenzo G., Di Trolio R., Delfino M., De Placido S. Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol 2005, 153(1):183-185.
65. Quereux G., Marques S., Nguyen J.M., Bedane C., D'incan M., Dereure O., et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 2008, 144(6):727-733.
66. Duvic M., Talpur R., Wen S., Kurzrock R., David C.L., Apisarnthanarax N., et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006, 7(1):51-58.
67. Marchi E., Alinari L., Tani M., Stefoni V., Pimpinelli N., Berti E., et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005, 104(11):2437-2441.
68. Zinzani P.L., Baliva G., Magagnoli M., Bendandi M., Modugno G., Gherlinzoni F., et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000, 18(13):2603-2606.
69. Berthelot C., Rivera A., Duvic M. Skin directed therapy for mycosis fungoides: a review. J Drugs Dermatol 2008, 7(7):655-666.
70. Herrmann J.J., Roenigk H.H., Hurria A., Kuzel T.M., Samuelson E., Rademaker A.W., et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995, 33(2 Pt 1):234-242.
71. Bunn P.A., Ihde D.C., Foon K.A. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas. Int J Cancer Suppl 1987, 1:9-13.
72. Jumbou O., N'Guyen J.M., Tessier M.H., Legoux B., Dréno B. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. Br J Dermatol 1999, 140(3):427-431.
73. Abbott R.A., Whittaker S.J., Morris S.L., Russell-Jones R., Hung T., Bashir S.J., et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009, 160(6):1299-1307.